Dr. Michael Brandkamp is leaving the HTGF to establish the European Circular Bioeconomy Fund

January 7, 2020

On December 31, 2019, Dr. Michael Brandkamp is leaving the High-Tech Gründerfonds (HTGF) after 14 very successful years in order to set up the new European growth fund (ECBF) as a general partner.

The European Commission has mandated the European Investment Bank (EIB) to launch this fund to close the gap in the financing of growth companies in the fields of sustainable chemistry, circular bioeconomy, blue economy and nutrition/personal care. Dr. Brandkamp’s enormous experience and network will be of great value to the new fund.

Dr. Michael Brandkamp’s large experience stems from participating in the launch of the HTGF in 2005 and -as a founding member- has been on board ever since He created essential parts of the business plan and implemented it as a managing director jointly with his management partner Dr. Alex von Frankenberg.

Within 14 years, three funds have been successfully initiated, more than 560 start-ups financed and more than 100 exits realised. Dr. Michael Brandkamp has anchored the networking of different actors deeply in the DNA of the HTGF from the very beginning. He is a convinced mediator between the worlds – science, start-ups and industry. He is convinced that respectful interaction  forms the basis for successful cooperation.

“The Advisory Board thanks Michael Brandkamp for his outstanding work for the HTGF, but also for his personal commitment to the German start-up ecosystem,” emphasizes Dr. Matthias Koehler, Chairman of the Investors’ Advisory Board (and Ministerial Director, Federal Ministry of Economics and Energy). “He will now make an important contribution elsewhere  to further improve the conditions for founders, which we very much welcome,” Koehler continued.

“I would like to take this opportunity to thank all colleagues at HTGF once again for their dedication and commitment over the past years, as well as all members of the Advisory Board for their support and advice. Together we have achieved excellent results for the HTGF, which we can be proud of. Now I am looking forward to developing great opportunities in the dynamic environment of the European circular economy,” says Michael Brandkamp.


About the High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 560 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences.

To date, external investors have injected over EUR 2 billion into the HTGF portfolio via more than 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

More information: www.htgf.de/en/

High-Tech  Gründerfonds Management GmbH
Stefanie Grüter
Schlegelstraße 2
53113 Bonn
T: +49 228 82300 188


About the European Circular Bioeconomy Fund (ECBF)
In a transforming economy, the European Circular Bioeconomy Fund (ECBF) invests and partners with ambitious and visionary entrepreneurs to accelerate late stage companies. ECBF relies on expertise and powerful networks to catalyze sustainable innovations and fuel business growth. We aim to fill a funding gap in the European (bio-) economy, bringing Europe’s excellent expertise in circular technologies to market. ECBF will be established in Luxembourg, advised by an experienced venture capital team within ECBF Management GmbH and managed by Hauck & Aufhäuser Funds Services S.A. (AIFM). Being a market standard growth stage venture capital fund, ECBF has the additional ability to focus on project financing as well as typical venture capital investment structures.

More information: www.ecbf.vc

Dr Michael Brandkamp, Dr Michael Nettersheim, Dr Dirk Sassmannshausen, Dr Peter Nieuwenhuize
T.: +49 170 2209067

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa